What is bioAffinity Technologies?
bioAffinity Technologies operates at the intersection of advanced diagnostics and life sciences, focusing on the development of proprietary platforms designed to improve clinical outcomes. The company occupies a specialized niche, utilizing non-invasive testing methodologies to address unmet needs in oncology and respiratory health. By integrating sophisticated data analytics with biological insights, bioAffinity Technologies aims to redefine standard diagnostic protocols, positioning itself as a high-growth entity within the broader healthcare technology landscape. Its market position is bolstered by a robust intellectual property portfolio and a strategic focus on high-value clinical applications.
How much funding has bioAffinity Technologies raised?
bioAffinity Technologies has raised a total of $13.3M across 6 funding rounds:
Series A
$4M
Debt
$150K
Debt
$5M
Debt
$212K
Share Placement
$2.5M
Share Placement
$1.4M
Series A (2017): $4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2020): $5M supported by Undisclosed
Debt (2021): $212K featuring PPP
Share Placement (2024): $2.5M backed by WallachBeth Capital
Share Placement (2025): $1.4M, investors not publicly disclosed
Key Investors in bioAffinity Technologies
WallachBeth Capital
WallachBeth is a leading provider of institutional execution services, specializing in unconflicted advice and intelligent trading solutions for complex market environments.
Undisclosed Investors
PPP
Public-Private Partnership
What's next for bioAffinity Technologies?
With the successful closure of this latest financing round, bioAffinity Technologies is well-positioned to execute its next phase of growth. The strategic allocation of these funds will likely prioritize the expansion of clinical trial pipelines and the enhancement of commercial infrastructure. As the company navigates the transition toward broader market adoption, management will focus on optimizing operational efficiencies and strengthening institutional partnerships. The infusion of capital provides a stable foundation for sustained innovation, allowing the firm to pursue aggressive growth targets while maintaining its commitment to scientific rigor and clinical excellence in the diagnostic space.
See full bioAffinity Technologies company page
